AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33046199 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 2
Study 33046199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain with Modic changes
Number of subjects: 2
Study 33046199 — intervention group
Group type: COMPARATOR
Intervention: Bacterial presence in discs
Number of subjects: 2
Study 35837739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 422
Study 35837739 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 422
Study 33446157 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on Theory of Planned Behavior (TPB)
Number of subjects: 94
Study 33446157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 94
Study 35655286 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong Capsule (ZZKZ)
Number of subjects: 480
Study 35655286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 32070297 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self‐Testing intervention with free HIVST kits provided every 30 days
Number of subjects: 0
Study 32070297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 0
Study 36194923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 51
Study 36194923 — intervention group
Group type: COMPARATOR
Intervention: Promestriene
Number of subjects: 51
Study 33610123 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent cediranib, followed by maintenance cediranib (arm C)
Number of subjects: 456
Study 33610123 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent cediranib, followed by maintenance placebo (arm B)
Number of subjects: 456
Study 33610123 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with placebo throughout (arm A, reference)
Number of subjects: 456
Study 32218424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoodia Parviflora (H. Parviflora) at 9 mg + 200 mg of fructo‐oligosaccharides, taken twice a day for 4 weeks
Number of subjects: 30
Study 32218424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoodia Parviflora (H. Parviflora)
Number of subjects: 30
Study 32218424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35989963 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation + robot-assisted hand therapy (HandTutor) for 1 hour during each session, 3 h/day, 2 days/week for 5 weeks
Number of subjects: 33
Study 35989963 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation alone for 3 h/day, 2 days/week for 5 weeks
Number of subjects: 33
Study 33030570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications (LLMs)
Number of subjects: 7592
Study 33030570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic statins
Number of subjects: 7592
Study 33030570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic statins
Number of subjects: 7592
Study 34038451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary dog visits (D)
Number of subjects: 174
Study 34038451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog visits with an activity (DA)
Number of subjects: 174
Study 34038451 — intervention group
Group type: COMPARATOR
Intervention: Visits with activity but no dog (A)
Number of subjects: 174
Study 32854145 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (BILITE design)
Number of subjects: 0
Study 32854145 — intervention group
Group type: COMPARATOR
Intervention: Conventional design (control)
Number of subjects: 0
Study 34059275 — intervention group
Group type: EXPERIMENTAL
Intervention: Test RDA∼58
Number of subjects: 220
Study 34059275 — intervention group
Group type: EXPERIMENTAL
Intervention: Test RDA∼77
Number of subjects: 220
Study 34059275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ref RDA∼80
Number of subjects: 220
Study 34059275 — intervention group
Group type: COMPARATOR
Intervention: Ref RDA∼120
Number of subjects: 220
Study 32392576 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 162
Study 32392576 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 162
Study 32392576 — intervention group
Group type: COMPARATOR
Intervention: Held-only controls
Number of subjects: 162
Study 33234641 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Intervention through Musical Engagement (CHIME)
Number of subjects: 124
Study 33234641 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 124
Study 34591168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lc-Hs (polyphenolic extract from Lippia citriodora and Hibiscus sabdariffa)
Number of subjects: 33
Study 34591168 — intervention group
Group type: COMPARATOR
Intervention: Pla (placebo)
Number of subjects: 33
Study 34591168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lc-Hs
Number of subjects: 33
Study 34591168 — intervention group
Group type: COMPARATOR
Intervention: Pla
Number of subjects: 33
Study 33283289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweeting in response to sexism
Number of subjects: 0
Study 33283289 — intervention group
Group type: COMPARATOR
Intervention: No-tweet control condition
Number of subjects: 0
Study 34839872 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation exercise
Number of subjects: 72
Study 34839872 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower limb barometry only)
Number of subjects: 72
Study 32023923 — intervention group
Group type: EXPERIMENTAL
Intervention: Confident Body, Confident Child (CBCC) resource + workshop
Number of subjects: 89
Study 32023923 — intervention group
Group type: EXPERIMENTAL
Intervention: nutrition booklet
Number of subjects: 89
Study 32023923 — intervention group
Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 89
Study 34551271 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Number of subjects: 27
Study 35420710 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking during the first month of treatment
Number of subjects: 1383
Study 35420710 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking during the last month of treatment
Number of subjects: 1383
Study 35420710 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning predictive model for heavy drinking between weekly/bi-weekly sessions
Number of subjects: 1383
Study 32096313 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 6 weeks
Number of subjects: 26
Study 32096313 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 9 weeks
Number of subjects: 26
Study 32096313 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-101 (4 mg/kg) and GSK2878175 (20 mg) for 12 weeks
Number of subjects: 26
Study 32096313 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2878175 long-acting injectable at 400 mg
Number of subjects: 26
Study 34428642 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS‐C + UC
Number of subjects: 121
Study 34428642 — intervention group
Group type: COMPARATOR
Intervention: UC-DT
Number of subjects: 121
Study 35467962 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing and relaxation exercises performed via telerehabilitation, twice daily for 4 weeks, with one session supervised by a physiotherapist.
Number of subjects: 50
Study 35467962 — intervention group
Group type: COMPARATOR
Intervention: Control group received an information session about COVID-19 via mobile phone video application.
Number of subjects: 50
Study 33082244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, restricted-calorie diet
Number of subjects: 235
Study 33082244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean, restricted-calorie diet
Number of subjects: 235
Study 33082244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, non-restricted-calorie diet
Number of subjects: 235
Study 33082244 — intervention group
Group type: COMPARATOR
Intervention: All diets (Low-fat, Mediterranean, Low-carbohydrate)
Number of subjects: 235
Study 34299702 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF) limited to an 8-h eating window
Number of subjects: 12
Study 34299702 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (non-TRF)
Number of subjects: 12
Study 34299702 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Number of subjects: 12
Study 32371536 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection evidence in renal tissue via light and electron microscopy
Number of subjects: 1
Study 32371536 — intervention group
Group type: EXPERIMENTAL
Intervention: Light microscopy findings
Number of subjects: 1
Study 32371536 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron microscopy findings
Number of subjects: 1
Study 33940496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (16 sessions of 30 minutes, twice a week)
Number of subjects: 33
Study 32634656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified photodynamic therapy (M-PDT)
Number of subjects: 24
Study 32634656 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (C-PDT)
Number of subjects: 24
Study 36091003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, intravenous drip, once every 3 weeks) combined with apatinib (250 mg, oral administration, once a day) plus capecitabine (1000 mg/m2, twice a day; after 2 weeks of oral administration, the drug was stopped for 1 week; course of treatment, 3 weeks)
Number of subjects: 47
Study 35990804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calanus oil supplementation with exercise program (n = 28)
Number of subjects: 55
Study 35990804 — intervention group
Group type: COMPARATOR
Intervention: Placebo with exercise program (n = 27)
Number of subjects: 55
Study 33835175 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐WORTH (5‐session culturally tailored group‐based intervention including a 1‐hour individual HIV testing and orientation session and 4 weekly 90‐minute group sessions)
Number of subjects: 352
Study 33835175 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐WORTH
Number of subjects: 352
Study 33835175 — intervention group
Group type: COMPARATOR
Intervention: Streamlined HIV testing control condition (1‐session of HIV testing and information)
Number of subjects: 352
Study 32324082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 4859
Study 32324082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 4859
Study 32324082 — intervention group
Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 4859
Study 33390189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 0
Study 33390189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 0
Study 33390189 — intervention group
Group type: COMPARATOR
Intervention: Social activity control
Number of subjects: 0
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility readiness score (median readiness score of 53.8% with IQR: 46.2 to 69.2%)
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge score for midwives in public facilities (median(IQR): 8(5 to 12))
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of severe pre-eclampsia diagnosis
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of magnesium sulfate for severe pre-eclampsia
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of anti-hypertensive drugs for severe pre-eclampsia
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of prophylactic use of aspirin to prevent pre-eclampsia
Number of subjects: 197
Study 33028310 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of prophylactic use of calcium to prevent pre-eclampsia
Number of subjects: 197
Study 36501186 — intervention group
Group type: COMPARATOR
Intervention: OliPhenolia® (OliP) 2 × 28 mL∙d−1 for 16 days
Number of subjects: 29
Study 36501186 — intervention group
Group type: COMPARATOR
Intervention: OliPhenolia® (OliP)
Number of subjects: 29
Study 36501186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 29
Study 33634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal type 1 diabetes (T1D)
Number of subjects: 218227
Study 33634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal type 2 diabetes (T2D)
Number of subjects: 218227
Study 33634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated gestational diabetes (GDM)
Number of subjects: 218227
Study 33634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated gestational diabetes (GDM)
Number of subjects: 218227
Study 33634964 — intervention group
Group type: COMPARATOR
Intervention: No diabetes during pregnancy
Number of subjects: 218227
Study 33115894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT, 9000 lux, 5000 K)
Number of subjects: 67
Study 33115894 — intervention group
Group type: COMPARATOR
Intervention: Dim red light therapy (DRLT, 100 lux, 2700 K)
Number of subjects: 67
Study 35170144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised gentamicin
Number of subjects: 15
Study 35170144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34414832 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-word stimuli via a smartphone application (3-min videos displaying positive-word stimuli every 5 seconds)
Number of subjects: 62
Study 34414832 — intervention group
Group type: COMPARATOR
Intervention: Control group using the same application but without positive-word stimuli in the videos
Number of subjects: 62
Study 34391230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic drainage therapy (LDT) applied for 45 minutes by an experienced physical therapist.
Number of subjects: 66
Study 34391230 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT: rest) received 45 minutes supine on the treatment table.
Number of subjects: 66
Study 34391230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LDT and control) during straight leg raise (SLR).
Number of subjects: 66
Study 34391230 — intervention group
Group type: COMPARATOR
Intervention: LDT and control groups.
Number of subjects: 66
Study 32903262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat, 22% monounsaturated fatty acids [MUFAs], and <50% carbohydrates)
Number of subjects: 805
Study 32903262 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (28% fat, 12% MUFAs, and >55% carbohydrates)
Number of subjects: 805
Study 32903262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 805
Study 34283210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild retinopathy (grades 1 and 2 combined)
Number of subjects: 9793
Study 34283210 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe retinopathy (grades 3 and 4 combined)
Number of subjects: 9793
Study 32239322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (2400 mg/day)
Number of subjects: 34
Study 32239322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32239322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 34
Study 35894893 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed Russian Current (SRC)
Number of subjects: 76
Study 35894893 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian Current (RC)
Number of subjects: 76
Study 35894893 — intervention group
Group type: COMPARATOR
Intervention: Voluntary Isometric Contraction (IC)
Number of subjects: 76
Study 34425828 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) administered within 6 to 12 hours after birth
Number of subjects: 156
Study 34425828 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 156
Study 34425828 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) in subgroup analysis of neonates with birthweight less than 1500g
Number of subjects: 156
Study 34425828 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group) in subgroup analysis of neonates with birthweight less than 1500g
Number of subjects: 156
Study 34425828 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk cell fractions (BMCFs) and routine care
Number of subjects: 156
Study 32200361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D pick-and-place task (10Cubes) using a virtual reality system with a Leap Motion Controller (LMC)
Number of subjects: 0
Study 32200361 — intervention group
Group type: COMPARATOR
Intervention: 2D equipment
Number of subjects: 0
Study 34287902 — intervention group
Group type: COMPARATOR
Intervention: CTG+CAF
Number of subjects: 30
Study 34287902 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMX+CAF
Number of subjects: 30
Study 32243885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition tDCS over right dorsolateral prefrontal cortex
Number of subjects: 92
Study 32243885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition tDCS over right posterior parietal cortex (PPC)
Number of subjects: 92
Study 32243885 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 92
Study 35411579 — intervention group
Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet)
Number of subjects: 36
Study 35411579 — intervention group
Group type: COMPARATOR
Intervention: TBP‐PI‐HBr reference (clinical trial tablet)
Number of subjects: 36
Study 35411579 — intervention group
Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet) under fed conditions
Number of subjects: 36
Study 35411579 — intervention group
Group type: EXPERIMENTAL
Intervention: TBP‐PI‐HBr test (registration tablet) and reference (clinical trial tablet)
Number of subjects: 36
Study 34082645 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme (acceptance and commitment training); n = 16; two group-format educational sessions.
Number of subjects: 34
Study 34082645 — intervention group
Group type: COMPARATOR
Intervention: No intervention; n = 18; control group.
Number of subjects: 34
Study 32843108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary ambulance
Number of subjects: 27
Study 32843108 — intervention group
Group type: COMPARATOR
Intervention: In-motion ambulance
Number of subjects: 27
Study 34459694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 2029
Study 34459694 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 2029
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 350
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 350
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 350
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 350
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 350
Study 34655316 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg plus 60 mg codeine
Number of subjects: 350
Study 34655316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 35545724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 468
Study 35545724 — intervention group
Group type: COMPARATOR
Intervention: Single-agent treatment of physician’s choice (TPC)
Number of subjects: 468
Study 35545724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) with prior CDK4/6 inhibitors
Number of subjects: 468
Study 35545724 — intervention group
Group type: COMPARATOR
Intervention: Single-agent treatment of physician’s choice (TPC) with prior CDK4/6 inhibitors
Number of subjects: 468
Study 33464670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use on days of alcohol consumption
Number of subjects: 96
Study 33464670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 96
Study 33464670 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cannabis use effects
Number of subjects: 96
Study 33872462 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (cocktail A: local anesthetics and corticosteroid)
Number of subjects: 44
Study 33872462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-carboxymethylcellulose (HA-CMC) (cocktail B: local anesthetics and HA-CMC)
Number of subjects: 44
Study 35905305 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally absorbed CBD (25 mg 3 times a day if <80 kg, or 50 mg 3 times a day if >80 kg) for 14 days postoperatively
Number of subjects: 99
Study 35905305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 34226219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) plus best practice treatment
Number of subjects: 200
Study 34226219 — intervention group
Group type: COMPARATOR
Intervention: Best practice treatment
Number of subjects: 200
Study 34226219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 200
Study 32723572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost cohort (exposed to societal cost information)
Number of subjects: 304
Study 32723572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost cohort (participants without previous CTS diagnosis)
Number of subjects: 304
Study 32723572 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no cost information)
Number of subjects: 304
Study 36063058 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open surgical treatment (Group 1)
Number of subjects: 112
Study 36063058 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous glue ablation (Group 2)
Number of subjects: 112
Study 36063058 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (Group 3)
Number of subjects: 112